GHRS

GH Research PLC

Add to Watchlist

Advanced Chart

13.530

+0.2(1.500%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

13.650

Open

13.310

VWAP

13.44

Vol

121.52K

Mkt Cap

839.26M

Low

13.1145

Amount

1.63M

EV/EBITDA(TTM)

Total Shares

52.03M

548.37M

EV/OCF(TTM)

P/S(TTM)

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.407

+114.04%

-0.262

+53.92%

-0.223

-2.9%

Estimates Revision

The market is revising No Change the revenue expectations for GH Research PLC (GHRS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 15.84%.

EPS Estimates for FY2025

Revise Downward

-5.5%

In Past 3 Month

Stock Price

Go Up

+15.84%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast GHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GHRS is 32.86 USD with a low forecast of 25.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 13.530

Low

25.00

Averages

32.86

High

40.00

Current: 13.530

Low

25.00

Averages

32.86

High

40.00

Cantor Fitzgerald

initiated

$25

2025-06-04

Reason

Cantor Fitzgerald

Price Target

$25

2025-06-04

initiated

Reason

Cantor Fitzgerald assumed coverage of GH Research with an Overweight rating and $25 price target. Data generated for psychedelics across a number of mental health disorders have been "transformational," and the unmet need is "enormous" and growing, the analyst tells investors in a research note. The firm says sees the psychedelic total addressable market ultimately reaching $50B per year, which would be roughly 1M-1.5M patients treated per year, still only modest penetration, and believes there is room for plenty of successful options and companies offering psilocybin and novel synthetic products.

Guggenheim

Eddie Hickman

Strong Buy

Initiates

$32

2025-03-13

Reason

Guggenheim

Eddie Hickman

Price Target

$32

2025-03-13

Initiates

Strong Buy

Reason

Guggenheim analyst Eddie Hickman initiated coverage of GH Research with a Buy rating and $32 price target.

RBC Capital

Brian Abrahams

Buy

Initiates

$31

2025-03-07

Reason

RBC Capital

Brian Abrahams

Price Target

$31

2025-03-07

Initiates

Buy

Reason

RBC Capital initiated coverage of GH Research with an Outperform rating and $31 price target. The firm says the "dramatic" antidepressive effects observed in the Phase IIb study of GH001, the company's psychedelic with "many favorable properties" facilitating administration and delivery, should be replicable in Phase III and position the drug as a treatment of choice in the future paradigm. With the stock off its post-data highs, RBC sees a "compelling entry point." While the stock's major near-term catalysts may be more limited, there should be appreciation as GH's development progress ensues and enthusiasm for psychedelics continues to build, contends the firm.

Stifel

Paul Matteis

Strong Buy

Maintains

$18 → $32

2025-02-27

Reason

Stifel

Paul Matteis

Price Target

$18 → $32

2025-02-27

Maintains

Strong Buy

Reason

Cantor Fitzgerald

Charles Duncan

Buy

Initiates

$14

2025-02-13

Reason

Cantor Fitzgerald

Charles Duncan

Price Target

$14

2025-02-13

Initiates

Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$40

2025-01-13

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$40

2025-01-13

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for GH Research PLC (GHRS.O) is -10.29, compared to its 5-year average forward P/E of -19.76. For a more detailed relative valuation and DCF analysis to assess GH Research PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-19.76

Current PE

-10.29

Overvalued PE

-3.67

Undervalued PE

-35.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-8.76

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-3.03

Undervalued EV/EBITDA

-14.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00